^
BIOMARKER:

EGFR amplification

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR amplification
NSCLC
gefitinib
Sensitive: B - Late Trials
EGFR amplification
SCCHN
afatinib
Sensitive: B - Late Trials
EGFR amplification
NSCLC
erlotinib
Sensitive: C2 – Inclusion Criteria
EGFR amplification
GBM
ABT-414
Sensitive: C2 – Inclusion Criteria
EGFR amplification
GBM
lapatinib
Sensitive: C2 – Inclusion Criteria
EGFR amplification
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive: C2 – Inclusion Criteria
EGFR amplification
GBM
KD019
Sensitive: C2 – Inclusion Criteria
EGFR amplification
Glioma
ABT-414
Sensitive: C2 – Inclusion Criteria
EGFR amplification
SCCHN
Immunotherapy
Resistant: C3 – Early Trials
EGFR amplification
Gastric Cancer
cetuximab
Sensitive: C3 – Early Trials
EGFR amplification
GBM
erlotinib
Resistant: C3 – Early Trials
EGFR amplification
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
EGFR amplification
Mucosal Melanoma
ipilimumab
Resistant: C3 – Early Trials
EGFR amplification
Mucosal Melanoma
nivolumab
Resistant: C3 – Early Trials
EGFR amplification
Mucosal Melanoma
nivolumab + ipilimumab
Resistant: C3 – Early Trials
EGFR amplification
Mucosal Melanoma
pembrolizumab
Resistant: C3 – Early Trials
EGFR amplification
CRC
cetuximab
Resistant: C3 – Early Trials
EGFR amplification
CRC
panitumumab
Sensitive: C3 – Early Trials
EGFR amplification
NSCLC
osimertinib
Resistant: C3 – Early Trials
EGFR amplification
Solid Tumor
ABSK-091
Sensitive: C3 – Early Trials
EGFR amplification
Lung Cancer
gefitinib
Resistant: C3 – Early Trials
EGFR amplification
Lung Cancer
icotinib
Resistant: C3 – Early Trials
EGFR amplification
NSCLC
bevacizumab + erlotinib
Sensitive: C3 – Early Trials
EGFR amplification
NSCLC
bevacizumab + gefitinib
Sensitive: C3 – Early Trials
EGFR amplification
SCCHN
pembrolizumab + afatinib
Sensitive: C3 – Early Trials
EGFR amplification
Gastric Cancer
EGFR inhibitor
Sensitive: C3 – Early Trials
EGFR amplification
Esophageal Cancer
EGFR inhibitor
Sensitive: C3 – Early Trials
EGFR amplification
NSCLC
KN046
Sensitive: C3 – Early Trials
EGFR amplification
Esophageal Squamous Cell Carcinoma
Z650
Sensitive: C3 – Early Trials
EGFR amplification
LUAD
afatinib
Sensitive: C4 – Case Studies
EGFR amplification
GBM
verteporfin
Sensitive: D – Preclinical
EGFR amplification
Glioma
talazoparib
Sensitive: D – Preclinical